WMWM
VRTX icon

Whitaker-Myers Wealth Managers’s Vertex Pharmaceuticals VRTX Stock Holding History

Whitaker-Myers Wealth Managers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-802
Closed -$373K – 140
2024
Q3 		$373K Buy
+802
New +$385K 0.12% 74

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Whitaker-Myers Wealth Managers's VRTX Position: Q4 2024 in Review

Whitaker-Myers Wealth Managers sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 802 shares — an estimated $373K sold.

Whitaker-Myers Wealth Managers first reported a position in VRTX in Q3 2024 and held it in 1 quarter. The position peaked at $373K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Whitaker-Myers Wealth Managers reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Whitaker-Myers Wealth Managers sold 802 Vertex Pharmaceuticals shares in Q4 2024, an estimated $373K.
  • Whitaker-Myers Wealth Managers first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Whitaker-Myers Wealth Managers's Vertex Pharmaceuticals position peaked at $373K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Whitaker-Myers Wealth Managers's 13F filing for Q4 2024, filed 15 Jan 2025.